Structure Therapeutics (GPCR) vs MeiraGTx (MGTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
MeiraGTx (MGTX) has outperformed Structure Therapeutics (GPCR) over the past year, gaining 22.0% versus a loss of 16.4%. Structure Therapeutics is the larger company by market cap ($1.82 billion vs $1.03 billion), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GPCR | MGTX |
|---|---|---|
| Share price | $25.54 | $10.69 |
| Market cap | $1.82B | $1.03B |
| 1-day change | -0.51% | +1.81% |
| YTD return | -63.28% | +34.47% |
| 1-year return | -16.40% | +22.03% |
| 5-year return | — | -25.14% |
| P/E ratio (TTM) | — | 12.29 |
| EPS (TTM) | $-3.03 | $0.87 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-141.20M | — |
| 52-week high | $94.90 | $15.35 |
| 52-week low | $25.09 | $6.62 |
| Distance from 52-week high | -73.09% | -30.36% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +314.17% | +159.59% |
| Average volume | 968.62K | 793.28K |
| Shares outstanding | 71.31M | 96.04M |
| Employees | 281 | 393 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGTX has outperformed GPCR by 38.4 percentage points over the past year.
About Structure Therapeutics
GPCR stock →Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral small molecule therapeutics to treat various chronic diseases with unmet medical needs in the United States. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, which is in two phase 2 clinical trials for the treatment of obesity, overweight, and related conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 281 employees
About MeiraGTx
MGTX stock →MeiraGTx Holdings plc, a clinical-stage genetic medicines company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases; neurodegenerative diseases; and xerostomia.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 393 employees
GPCR vs MGTX FAQ
Which is bigger, Structure Therapeutics or MeiraGTx?
Structure Therapeutics (GPCR) is larger, with a market capitalization of $1.82B compared with $1.03B for MeiraGTx (MGTX).
Which stock has performed better over the past year, GPCR or MGTX?
MGTX returned +22.03% over the past 12 months, compared with -16.40% for GPCR (price return, excluding dividends). Past performance does not predict future results.
Are Structure Therapeutics and MeiraGTx in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Structure Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for MeiraGTx.